Am J Gastroenterol

1. SAWAS T, Davitkov P, Zhou M, Eluri S, et al
   Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.
   Am J Gastroenterol. 2026;121:2411-2422.
   

   >> Share

   
   

   
   Ann Surg

2. KRAUSS DT, van der Sluis PSL, Schiffmann LM, Schlosser HA, et al
   The Impact of Robotics on Benchmarking Criteria for the Surgical Treatment of Esophageal Cancer in Western Centers- An Evaluation Using the IDEAL Framework.
   Ann Surg. 2026 Oct 1. doi: 10.1097/SLA.0000000000007230.
   

   >> Share

   
   

   
   Anticancer Res

3. KAMM W, Zhang QI, Mortensen L, Wuertz B, et al
   Triptolide as a Chemosensitizer in Human Papillomavirus Head and Neck Squamous Cell Carcinoma Through TP53.
   Anticancer Res. 2026;46:5359-5373.
   

   >> Share

   
   
4. LEE ST, Chen PN, Chen KM, Wu YC, et al
   Acacetin Promotes Cell Death and Inhibits Migration in Follicular Thyroid Cells.
   Anticancer Res. 2026;46:5453-5465.
   

   >> Share

   
   
5. WANG R, Zhang QI, Fan R, Gao Y, et al
   Alpha-catenin Mutation-associated Synchronous Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma With Numerous Adenomatoid Nodules.
   Anticancer Res. 2026;46:5775-5779.
   

   >> Share

   
   
6. KIM NR, Cho SJ
   Molecular Profiling of Archival Tonsillar Squamous Cell Carcinoma in a Korean Pre-HPV-vaccination Cohort.
   Anticancer Res. 2026;46:5679-5687.
   

   >> Share

   
   
7. WANG X, Miao Q, Liu X, Liu F, et al
   FXR1 Promotes Esophageal Squamous Cell Carcinoma via JAK2/STAT3/B7-H3 Pathway.
   Anticancer Res. 2026;46:5467-5481.
   

   >> Share

   
   
8. TAMURA H, Otsuki Y, Hosokawa A
   Pembrolizumab plus Chemotherapy for Synchronous Multiple Primary Esophageal and Gingival Squamous Cell Carcinomas.
   Anticancer Res. 2026;46:5759-5766.
   

   >> Share

   
   

   
   BMC Cancer

9. ALNOUR A
   Pleomorphic adenoma: does the immunohistochemical profile direct the clinical profile: retrospective study and review of literature.
   BMC Cancer. 2026;26:1152.
   

   >> Share

   
   
10. ALI A, Bari MF, Arshad S, Wahid M, et al
    Spatial profiling of tissue-resident memory T cells reveals stromal IL-15 niches and a paradoxical CD103(+) phenotype predicting survival in oral squamous cell carcinoma.
    BMC Cancer. 2026;26:1169.
    

    >> Share

    
    
11. WANG W, Zhang X, Sun X, Wang L, et al
    Comparative efficacy and safety of first-line immunotherapy- and targeted therapy-based regimens for advanced gastric and gastroesophageal junction cancer: a network meta-analysis.
    BMC Cancer. 2026;26:1146.
    

    >> Share

    
    
12. GRUETER K, Sander N, Coen L, Husken S, et al
    Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma.
    BMC Cancer. 2026;26:1149.
    

    >> Share

    
    

    
    Br J Cancer

13. TENGLER L, Jackson EK, Bieback K, Roth R, et al
    Small extracellular vesicles from the plasma of head and neck cancer patients induce dysfunctional T cell phenotypes.
    Br J Cancer. 2026 Sep 26. doi: 10.1038/s41416-026-03606.
    

    >> Share

    
    

    
    Br J Oral Maxillofac Surg

14. KUMAR S, Gupta N, Kumar Singh S, Srinivasan H, et al
    Comment on "Exploring prevalence of Head and Neck Cancer and Skin Cancer Kent and Medway to identify health inequity".
    Br J Oral Maxillofac Surg. 2026 Sep 16:S0266-4356(26)00239.
    

    >> Share

    
    
15. BAGCHI PR, Yennemadi SR
    Letter to the Editor regarding "Textbook Outcome follow up: bridging short-term success and long-term outcomes in head and neck cancer".
    Br J Oral Maxillofac Surg. 2026 Aug 30:S0266-4356(26)00224.
    

    >> Share

    
    

    
    Clin Cancer Res

16. MALASSIGNE V, Puech J, Imbeaud S, Auperin A, et al
    HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2026;32:4434-4447.
    

    >> Share

    
    
17. WYRWICZ L, Dechaphunkul A, Lee JS, Turpin A, et al
    A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.
    Clin Cancer Res. 2026;32:4319-4330.
    

    >> Share

    
    

    
    Dis Esophagus

18. OKUI J, Lyu HG, Prakash LR, Li JJ, et al
    Automated detection of gastroesophageal adenocarcinoma recurrence from electronic health records.
    Dis Esophagus. 2026;39:doag109.
    

    >> Share

    
    

    
    Head Neck

19. XU R, Huang MJ, Jiang ZH, Liu L, et al
    Neoadjuvant Anlotinib Plus Paclitaxel-Cisplatin for Technically Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Prospective Single-Arm Phase II Study.
    Head Neck. 2026 Sep 30. doi: 10.1002/hed.70501.
    

    >> Share

    
    
20. SAVOIA G, Hier MP, Sadeghi N, Mlynarek A, et al
    Pretreatment Cachexia Index Is Associated With Severe Treatment Toxicity and Overall Survival in HPV-Negative Head and Neck Squamous Cell Carcinoma.
    Head Neck. 2026 Oct 1. doi: 10.1002/hed.70500.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

21. HORN A, Sherman E, Lee N, Yu Y, et al
    A Phase 2 Study of Postoperative Xevinapant and Chemoradiation for Patients With High-Risk Resected Head and Neck Squamous Cell Carcinomas.
    Int J Radiat Oncol Biol Phys. 2026 Sep 17:S0360-3016(26)04231.
    

    >> Share

    
    
22. WANG Q, Jin D, Wang Y, Wu L, et al
    WITHDRAWN: Metastatic Lymph Node Station Classification in Esophageal Cancer via Prior-Guided Supervision and Station-Aware Mixture-of-Experts.
    Int J Radiat Oncol Biol Phys. 2025;123.
    

    >> Share

    
    

    
    J Laryngol Otol

23. CHIARI F, Carosi C, Fermi M, Presutti L, et al
    Surgical management of parapharyngeal vagal schwannomas: a systematic review and practical considerations for approach selection.
    J Laryngol Otol. 2026;140:954-962.
    

    >> Share

    
    
24. SATTAR Z, Mowat A, Barraclough J
    Septal melanoma: does surgical excision confer a potential survival benefit? A single centre's experience and literature review.
    J Laryngol Otol. 2026 Jun 23:1-20. doi: 10.1017/S0022215126105283.
    

    >> Share

    
    

    
    J Oral Maxillofac Surg

25. NOY R, Graieb M, Shkedy Y, Taha A, et al
    Outcomes of Free-Flap Reconstructive Microsurgery in Frail Head and Neck Patients.
    J Oral Maxillofac Surg. 2026;84:1690-1697.
    

    >> Share

    
    
26. WARD BB, Kademani D, Qaisi M, Shupak RP, et al
    American Association of Oral and Maxillofacial Surgeons' Position Paper on the Management of the Clinically Negative Neck (cN0) in cT1N0 and cT2N0 Oral Squamous Cell Carcinoma.
    J Oral Maxillofac Surg. 2026;84:1675-1689.
    

    >> Share

    
    

    
    Oral Oncol

27. YANAN D, Zhao T, Chuanliang S, Junzheng W, et al
    Comments on: prognostic value of the 5-Item Modified Frailty Index in elderly patients undergoing free flap reconstruction for head and neck cancer.
    Oral Oncol. 2026;182:108154.
    

    >> Share

    
    
28. LONG CQ
    Interpreting distant metastasis risk in MRI-Defined N3 nasopharyngeal carcinoma in the presence of competing events.
    Oral Oncol. 2026;182:108160.
    

    >> Share

    
    
29. SMITH JD, Santiago R, Doerfler R, Harris MK, et al
    The impact of regional lymph node depletion on response to anti-PD-1 therapy in recurrent and metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2026;182:108155.
    

    >> Share

    
    
30. URAGUCHI K, Rikitake R, Tsumura M, Ando M, et al
    Board-certified facilities and survival in head and neck cancer in Japan: A hospital-based cancer registry study.
    Oral Oncol. 2026;182:108152.
    

    >> Share

    
    

    
    Radiology

31. RAI P, Bhatt AA
    Rethinking the Role of CT- and MRI-detected Extranodal Extension in Nasopharyngeal Carcinoma: An Early Career Perspective.
    Radiology. 2026;320:e262601.
    

    >> Share

    
    

    
    Thyroid

32. ALZAHRANI AS, Benito A, Alghamdi B, Alqahtani A, et al
    Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET-Negative, HRAS-, and NF1-Mutated Metastatic Medullary Thyroid Carcinoma.
    Thyroid. 2026 Oct 1:10507256261493665. doi: 10.1177/10507256261493665.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share